I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
Cancer is an elusive foe. Rarely does a single therapy or intervention knock it out, which is why drug combinations are at the top of the agenda for doctors and researchers,... Read more »
So much for lying low. Investors led by Martin Shkreli have bought a majority of the shares of failed South San Francisco, CA-based KaloBios Pharmaceuticals, which has been in dire straits... Read more »
Our annual San Francisco Bay Area biotech forum is right around the corner. This year we’re highlighting the most disruptive areas of life science and the Bay Area scientists, entrepreneurs, and... Read more »
We’re one month away from our annual San Francisco Bay Area biotech forum on December 10, and we’re excited to share the lineup with you. This year, we’re focusing on... Read more »
[Corrected, 11/12/15, 4:17pm. See below.] The way pharmaceuticals work is often described as keys fitting locks. A drug goes into the body and finds its target because it matches... Read more »
Japanese drug firm Astellas Pharma announced late Monday it has agreed to buy Ocata Therapeutics (NASDAQ: OCAT), which is developing regenerative medicines for eye diseases. It’s an all-cash deal worth... Read more »
There were drips and drabs of news out west this week, but compared to recent weeks with former Silicon Valley darling Theranos taking a beating, or 23andMe revving its engines, it’s... Read more »
Here and there, the genetic information of a cancer patient has helped a doctor find that person the right drug or steer her away from the wrong one. But the use... Read more »
Biotech venture group Flagship Ventures is doubling down on the microbiome. The Cambridge, MA-based firm, which specializes in building new therapeutics companies in stealth mode, today launched Evelo Therapeutics, its second... Read more »
[Corrected 11/3/15, 1:18pm. See below.] As Xconomy reported Friday, the U.S. Securities and Exchange Commission has finally filled in the missing pieces in the equity crowdfunding puzzle, giving... Read more »
After eight years, more than $20 million raised, and a handful of different business plans, genomics firm Knome has been acquired by tiny Tute Genomics of Provo, UT, for what appears... Read more »
[Corrected 11/2/15, 12:30 pm. See below.] Mom and Pop, you can now buy shares in the bakery down the street, or in your son’s girlfriend’s sister’s tech startup. That,... Read more »
Whether the unprecedented biotech boom has undergone a slight correction or is shuffling toward bear territory, veteran venture group Frazier Healthcare Partners has a new pool of cash to invest. The... Read more »
“Take two aspirin and call me in the morning” is the punch line to decades’ worth of doctor-diagnosis jokes, but San Francisco software company Enlitic doesn’t see the humor in it.... Read more »
Biotech executives and investors gathered in San Francisco this week to size one another up, schmooze, and eat rubber chicken lunches—although the vegetarian ravioli option wasn’t bad. It was the best-attended... Read more »
[Corrected 10/29/15, 12:52 am. See below.] Boom or not, there’s always a need for startup capital in biotech. A new source is about to emerge. The founders of LabCentral... Read more »
The consumer genome. You’ll hear that phrase enough the next couple years that it will gain both the weight and lightness of inevitability.
It will feel inevitable because, as we’ve been... Read more »
We were stuck for a couple days in a Nobel vortex. Speculation about a Nobel Prize in chemistry for University of California, Berkeley scientist Jennifer Doudna and her gene-editing research partner,... Read more »
Biomedical innovation is shaking up societies around the world, prompting advances no one would have imagined a decade ago, and stirring debates about ethical and financial costs. The San Francisco Bay... Read more »
December 10, 2015
© 2007-2015, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.